eligibility_summary
Eligibility: ECOG 0–1, life ≥3 mo, advanced/metastatic solid tumors—Part 1: any after/intolerant to standard therapy, Part 2: selected tumors after ≥1 systemic line, tumor tissue available, measurable/evaluable by RECIST 1.1, adequate organ function, contraception. Exclude: other cancer <3 y, active/unstable CNS mets, major cardiac/respiratory disease, unresolved AEs, active infections (HIV/HBV/HCV), prior topo‑I ADC or B7‑H3, recent therapies/immunosuppression/investigational use, drug abuse, pregnancy/lactation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: 7MW3711, an intravenous antibody–drug conjugate (ADC) given Q3W. Mechanism of action: a monoclonal antibody binds a tumor-associated surface antigen broadly expressed on solid tumors, is internalized, and releases a cytotoxic payload to kill antigen-positive cells. Likely target/payload (inferred from exclusions): prior B7‑H3–targeted agents and prior topoisomerase I inhibitor–containing ADCs are excluded, suggesting 7MW3711 targets B7‑H3 (CD276) and may use a topo‑I inhibitor payload, the protocol does not explicitly confirm this. Cells/pathways targeted: antigen-positive tumor cells (and possibly tumor stroma) expressing B7‑H3, ADC-mediated delivery of a DNA-damaging payload after internalization.